Atea Pharmaceuticals(AVIR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash and investments of $301.8 million, indicating a strong financial position to support ongoing clinical programs [24] - The funds expended in 2025 were primarily directed towards the advancement of the HCV Phase 3 program and discovery efforts for HEV treatment [24] - R&D expenses increased in 2025 compared to 2024, driven by external spending on the HCV Phase 3 clinical development [25] Business Line Data and Key Metrics Changes - The global Phase 3 HCV program is on track, with enrollment completed for the North American trial, C-BEYOND, involving over 880 patients [6] - The company anticipates top-line results for C-BEYOND by mid-year and for C-FORWARD by year-end [6][27] - The HEV program has been initiated with AT-587 as the lead product candidate, with plans to start a first-in-human study mid-year [6][27] Market Data and Key Metrics Changes - The incidence of new chronic Hepatitis C infections in the U.S. has increased to approximately 4 million, with only 85,000 patients treated annually [8] - The market opportunity for chronic HEV treatment is estimated to be between $750 million and $1 billion per year, addressing a significant unmet need [20] Company Strategy and Development Direction - The company aims to deliver top-line Phase 3 results for HCV treatments that feature high efficacy, short treatment duration, and low risk of drug-drug interactions [27] - The HEV program represents a strategic expansion of the antiviral pipeline, targeting a vulnerable patient population with no approved treatments available [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving enrollment targets for both C-BEYOND and C-FORWARD trials, indicating a robust clinical development strategy [30] - The company is focused on maintaining financial discipline while advancing its HCV and HEV product candidates, projecting a cash runway extending through 2027 [25][26] Other Important Information - The company returned $25 million to stockholders through a share repurchase program in 2025, reflecting a commitment to drive value for stockholders [24] - The commercial package for HCV will include a blister card for convenience and adherence, with a simple 4-week dosing regimen [17] Q&A Session Summary Question: Does achieving enrollment targets for the cirrhotic population for C-BEYOND increase confidence in C-FORWARD? - Management confirmed that they are on track to achieve overall targets for both trials, with cirrhotic enrollment not being an issue [30] Question: Can you discuss the commercial landscape and pricing evolution for HCV treatments? - Management indicated that the specialty market for DAA is well understood, with stable pricing trends and positive interest from payers regarding the new regimen [34][35] Question: How does the primary endpoint analysis for C-BEYOND affect the potential market uptake? - Management noted that the modified intent-to-treat analysis allows for flexibility in dosing, and the positive profile of the regimen is expected to resonate well with prescribers [39][40]